Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Rubius Therapeutics, Inc. (RUBY)  
$0.06 0.00 (0.00%) as of 4:30 Fri 12/29


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 89,770,000
Market Cap: 5.12(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.01615 - $0.057
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Rubius Therapeutics is a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to develop a class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases. Co.'s platform, RED PLATFORM, biologically engineers and cultures allogeneic red blood cell therapies that enable multiple applications, or modalities. Co.'s immune stimulation for the treatment of cancer includes RTX-240, which is designed to stimulate the immune system by activating and expanding both NK and CD8+ memory T cells to generate an anti-tumor response; and RTX-224, which is designed as an immune agonist of both adaptive and innate responses.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 0 38,281
Total Sell Value $0 $0 $0 $11,362
Total People Sold 0 0 0 3
Total Sell Transactions 0 0 0 6
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 65
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Appelhans Dannielle CEO and President   •       –      –    2023-02-24 4 S $0.13 $1,323 D/D (10,385) 0 83%     
   Cagnoni Pablo J Director   –       •      –    2023-02-01 4 S $0.25 $2,112 D/D (8,448) 66,082 93%     
   Appelhans Dannielle CEO and President   •       –      –    2023-02-01 4 S $0.25 $970 D/D (3,878) 10,385 93%     
   Appelhans Dannielle CEO and President   •       –      –    2023-01-31 4 OE $0.00 $0 D/D 7,500 14,263     -
   Turka Laurence A. Chief Scientific Officer   •       –      –    2023-01-31 4 S $0.24 $622 D/D (2,593) 18,391 92%     
   Turka Laurence A. Chief Scientific Officer   •       –      –    2023-01-31 4 OE $0.00 $0 D/D 8,625 20,984     -
   Cagnoni Pablo J Director   –       •      –    2023-01-31 4 S $0.24 $1,745 D/D (7,240) 74,530 92%     
   Cagnoni Pablo J Director   –       •      –    2023-01-31 4 OE $0.00 $0 D/D 25,000 81,770     -
   Turka Laurence A. Chief Scientific Officer   •       –      –    2023-01-29 4 OE $0.00 $0 D/D 7,438 12,359     -
   Cagnoni Pablo J Director   –       •      –    2023-01-29 4 OE $0.00 $0 D/D 21,250 56,770     -
   Appelhans Dannielle Chief Operating Officer   •       –      –    2022-08-10 4 S $0.80 $4,590 D/D (5,737) 6,763 81%     
   Appelhans Dannielle Chief Operating Officer   •       –      –    2022-08-09 4 OE $0.00 $0 D/D 12,500 12,500     -
   Epstein David R Director   –       •      –    2022-04-21 4 B $1.44 $43,329 D/D 30,000 4,720,012 2.39 -46%     
   Keson-Brookes Maiken CLO & Corp. Secretary   •       –      –    2022-02-01 4 S $6.57 $17,957 D/D (2,732) 5,343 86%     
   Cagnoni Pablo J CEO and President   •       •      –    2022-02-01 4 S $6.57 $44,236 D/D (6,730) 35,520 86%     
   Turka Laurence A. Chief Scientific Officer   •       –      –    2022-02-01 4 S $6.57 $16,544 D/D (2,517) 4,921 86%     
   Keson-Brookes Maiken CLO & Corp. Secretary   •       –      –    2022-01-29 4 OE $0.00 $0 D/D 8,075 8,075     -
   Cagnoni Pablo J CEO and President   •       •      –    2022-01-29 4 OE $0.00 $0 D/D 21,250 42,250     -
   Turka Laurence A. Chief Scientific Officer   •       –      –    2022-01-29 4 OE $0.00 $0 D/D 7,438 7,438     -
   Afeyan Noubar Director   –       •       •   2021-03-19 4 B $29.00 $6,090,000 I/I 210,000 2,633,703 2.25 -10%     
   Keson-Brookes Maiken CLO & Corp. Secretary   •       –      –    2021-03-15 4 AS $20.24 $505,965 D/D (25,000) 0 -28%     
   Keson-Brookes Maiken CLO & Corp. Secretary   •       –      –    2021-03-15 4 OE $7.70 $192,500 D/D 25,000 25,000     -
   Epstein David R Director   –       •      –    2021-02-11 4 AS $14.93 $398,560 D/D (26,704) 4,690,012 85%     
   Epstein David R Director   –       •      –    2021-02-10 4 AS $14.79 $109,525 D/D (7,404) 4,716,716 72%     
   Epstein David R Director   –       •      –    2021-02-09 4 AS $14.83 $31,146 D/D (2,100) 4,724,120 70%     
  65 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us